{"pmid":32387058,"title":"Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups.","text":["Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups.","The Covid-19 pandemic is profoundly changing the organization of healthcare access. This is particularly so for peritoneal neoplastic diseases, for which curative treatment mobilizes substantial personnel, operating room and intensive care resources. The BIG-RENAPE and RENAPE groups have made tentative proposals for prioritizing care provision. A tightening of the usual selection criteria is needed for curative care: young patients with few or no comorbidities and limited peritoneal extension. It is desirable to prioritize disease conditions for which cytoreduction surgery with or without associated hyperthermic intraoperative peritoneal chemotherapy (HIPEC) is the gold-standard treatment, and for which systemic chemotherapy cannot be a temporary or long-term alternative: pseudomyxoma peritonei, resectable malignant peritoneal mesotheliomas, peritoneal metastases of colorectal origin if they are resectable and unresponsive to systemic chemotherapy after up to 12 courses, first-line ovarian carcinomatosis if resectable or in interval surgery after at most six courses of systemic chemotherapy. Addition of HIPEC must be discussed case by case in an expert center. The prioritization of indications must consider local conditions and the phase of the epidemic to allow optimal peri-operative care.","J Visc Surg","Glehen, O","Kepenekian, V","Bouche, O","Gladieff, L","Honore, C","32387058"],"abstract":["The Covid-19 pandemic is profoundly changing the organization of healthcare access. This is particularly so for peritoneal neoplastic diseases, for which curative treatment mobilizes substantial personnel, operating room and intensive care resources. The BIG-RENAPE and RENAPE groups have made tentative proposals for prioritizing care provision. A tightening of the usual selection criteria is needed for curative care: young patients with few or no comorbidities and limited peritoneal extension. It is desirable to prioritize disease conditions for which cytoreduction surgery with or without associated hyperthermic intraoperative peritoneal chemotherapy (HIPEC) is the gold-standard treatment, and for which systemic chemotherapy cannot be a temporary or long-term alternative: pseudomyxoma peritonei, resectable malignant peritoneal mesotheliomas, peritoneal metastases of colorectal origin if they are resectable and unresponsive to systemic chemotherapy after up to 12 courses, first-line ovarian carcinomatosis if resectable or in interval surgery after at most six courses of systemic chemotherapy. Addition of HIPEC must be discussed case by case in an expert center. The prioritization of indications must consider local conditions and the phase of the epidemic to allow optimal peri-operative care."],"journal":"J Visc Surg","authors":["Glehen, O","Kepenekian, V","Bouche, O","Gladieff, L","Honore, C"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387058","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jviscsurg.2020.04.013","keywords":["coronavirus","covid-19","peritoneal metastases","primary peritoneal tumor"],"locations":["ovarian"],"topics":["Prevention"],"weight":1,"_version_":1666428892757360641,"score":9.490897,"similar":[{"pmid":32328206,"pmcid":"PMC7177067","title":"[Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic Proposals for prioritization from the RENAPE and BIG-RENAPE groups].","text":["[Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic Proposals for prioritization from the RENAPE and BIG-RENAPE groups].","The Covid-19 pandemic is profoundly changing the organization of healthcare access. This is particularly so for peritoneal neoplastic diseases, for which curative treatment mobilizes substantial personnel, operating room and intensive care resources. The BIG-RENAPE and RENAPE groups have made tentative proposals for prioritizing care provision.A tightening of the usual selection criteria is needed for curative care: young patients with few or no comorbidities and limited peritoneal extension. It is desirable to prioritize disease conditions for which cytoreduction surgery with or without associated hyperthermic intraoperative peritoneal chemotherapy (HIPEC) is the gold-standard treatment, and for which systemic chemotherapy cannot be a temporary or long-term alternative: pseudomyxoma peritonei, resectable malignant peritoneal mesotheliomas, peritoneal metastases of colorectal origin if they are resectable and unresponsive to systemic chemotherapy after up to 12 courses, first-line ovarian carcinomatosis if resectable or in interval surgery after at most six courses of systemic chemotherapy. Addition of HIPEC must be discussed case by case in an expert center. The prioritization of indications must consider local conditions and the phase of the epidemic to allow optimal peri-operative care.","Glehen, O","Kepenekian, V","Bouche, O","Gladieff, L","Honore, C","Big-Renape, Renape-","32328206"],"abstract":["The Covid-19 pandemic is profoundly changing the organization of healthcare access. This is particularly so for peritoneal neoplastic diseases, for which curative treatment mobilizes substantial personnel, operating room and intensive care resources. The BIG-RENAPE and RENAPE groups have made tentative proposals for prioritizing care provision.A tightening of the usual selection criteria is needed for curative care: young patients with few or no comorbidities and limited peritoneal extension. It is desirable to prioritize disease conditions for which cytoreduction surgery with or without associated hyperthermic intraoperative peritoneal chemotherapy (HIPEC) is the gold-standard treatment, and for which systemic chemotherapy cannot be a temporary or long-term alternative: pseudomyxoma peritonei, resectable malignant peritoneal mesotheliomas, peritoneal metastases of colorectal origin if they are resectable and unresponsive to systemic chemotherapy after up to 12 courses, first-line ovarian carcinomatosis if resectable or in interval surgery after at most six courses of systemic chemotherapy. Addition of HIPEC must be discussed case by case in an expert center. The prioritization of indications must consider local conditions and the phase of the epidemic to allow optimal peri-operative care."],"authors":["Glehen, O","Kepenekian, V","Bouche, O","Gladieff, L","Honore, C","Big-Renape, Renape-"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32328206","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jchirv.2020.04.011","keywords":["coronavirus","covid-19","peritoneal metastases","primary peritoneal tumor"],"locations":["ovarian"],"weight":0,"_version_":1666138494730240000,"score":2319.976},{"pmid":32385569,"title":"COVID-19 not detected in peritoneal fluid: a case of laparoscopic appendicectomy for acute appendicitis in a COVID-19-infected patient.","text":["COVID-19 not detected in peritoneal fluid: a case of laparoscopic appendicectomy for acute appendicitis in a COVID-19-infected patient.","PURPOSE: COVID-19 greatly affected millions and affected the way we practice with heightened posture in the way we treat surgical patients. Surgical consensus guidelines are recommending caution in the use of laparoscopy for the theoretical possibility of viral transmission from aerosolization of tissue and peritoneal fluid during surgery. However, there has yet to be proof of COVID-19 being present in peritoneal fluid, justifying the consensus statements. We aim to assess the presence of COVID-19 in peritoneal fluid. METHODS: We performed a laparoscopic appendicectomy for a COVID-19-infected patient with acute appendicitis. Peritoneal fluid and peritoneal washings were collected and sent for COVID-19 PCR. RESULTS: The peritoneal fluid sample collected on entry and at the end of the operation was negative for COVID-19 on PCR. The patient had an uneventful recovery from surgery. CONCLUSIONS: This case revealed that COVID-19 was not detected in peritoneal fluid and peritoneal washings in a patient infected with COVID-19. This study provides novel preliminary data in the investigation of COVID-19 transmission from laparoscopy-related aerosolization.","Langenbecks Arch Surg","Ngaserin, Sabrina Hui-Na","Koh, Frederick H","Ong, Biauw-Chi","Chew, Min-Hoe","32385569"],"abstract":["PURPOSE: COVID-19 greatly affected millions and affected the way we practice with heightened posture in the way we treat surgical patients. Surgical consensus guidelines are recommending caution in the use of laparoscopy for the theoretical possibility of viral transmission from aerosolization of tissue and peritoneal fluid during surgery. However, there has yet to be proof of COVID-19 being present in peritoneal fluid, justifying the consensus statements. We aim to assess the presence of COVID-19 in peritoneal fluid. METHODS: We performed a laparoscopic appendicectomy for a COVID-19-infected patient with acute appendicitis. Peritoneal fluid and peritoneal washings were collected and sent for COVID-19 PCR. RESULTS: The peritoneal fluid sample collected on entry and at the end of the operation was negative for COVID-19 on PCR. The patient had an uneventful recovery from surgery. CONCLUSIONS: This case revealed that COVID-19 was not detected in peritoneal fluid and peritoneal washings in a patient infected with COVID-19. This study provides novel preliminary data in the investigation of COVID-19 transmission from laparoscopy-related aerosolization."],"journal":"Langenbecks Arch Surg","authors":["Ngaserin, Sabrina Hui-Na","Koh, Frederick H","Ong, Biauw-Chi","Chew, Min-Hoe"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32385569","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s00423-020-01891-2","keywords":["covid-19","laparoscopy","peritoneal fluid","safety","surgery"],"topics":["Case Report"],"weight":1,"_version_":1666340102059589632,"score":348.2753},{"pmid":32222433,"title":"[Guidelines for surgical management of gynaecological cancer during pandemic COVID-19 period - FRANCOGYN group for the CNGOF].","text":["[Guidelines for surgical management of gynaecological cancer during pandemic COVID-19 period - FRANCOGYN group for the CNGOF].","INTRODUCTION: Recommendations for the management of patients with gynecological cancer during the COVID-19 pandemic period. MATERIAL AND METHOD: Recommendations based on the consensus conference model. RESULTS: In the case of a COVID-19 positive patient, surgical management should be postponed for at least 15 days. For cervical cancer, the place of surgery must be re-evaluated in relation to radiotherapy and Radio-Chemotherapy-Concomitant and the value of lymph node staging surgeries must be reviewed on a case-by-case basis. For advanced ovarian cancers, neo-adjuvant chemotherapy should be favored even if primary cytoreduction surgery could be envisaged. It is lawful not to offer hyperthermic intraperitoneal chemotherapy during a COVID-19 pandemic. In the case of patients who must undergo interval surgery, it is possible to continue the chemotherapy and to offer surgery after 6 cycles of chemotherapy. For early stage endometrial cancer, in case of low and intermediate preoperative ESMO risk, hysterectomy with bilateral annexectomy associated with a sentinel lymph node procedure should be favored. It is possible to consider postponing surgery for 1 to 2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For high ESMO risk, it ispossible to favor the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) in order to omit pelvic and lumbar-aortic lymphadenectomies. CONCLUSION: During COVID-19 pandemic, patients suffering from cancer should not lose life chance, while limiting the risks associated with the virus.","Gynecol Obstet Fertil Senol","Akladios, C","Azais, H","Ballester, M","Bendifallah, S","Bolze, P-A","Bourdel, N","Bricou, A","Canlorbe, G","Carcopino, X","Chauvet, P","Collinet, P","Coutant, C","Dabi, Y","Dion, L","Gauthier, T","Graesslin, O","Huchon, C","Koskas, M","Kridelka, F","Lavoue, V","Lecointre, L","Mezzadri, M","Mimoun, C","Ouldamer, L","Raimond, E","Touboul, C","32222433"],"abstract":["INTRODUCTION: Recommendations for the management of patients with gynecological cancer during the COVID-19 pandemic period. MATERIAL AND METHOD: Recommendations based on the consensus conference model. RESULTS: In the case of a COVID-19 positive patient, surgical management should be postponed for at least 15 days. For cervical cancer, the place of surgery must be re-evaluated in relation to radiotherapy and Radio-Chemotherapy-Concomitant and the value of lymph node staging surgeries must be reviewed on a case-by-case basis. For advanced ovarian cancers, neo-adjuvant chemotherapy should be favored even if primary cytoreduction surgery could be envisaged. It is lawful not to offer hyperthermic intraperitoneal chemotherapy during a COVID-19 pandemic. In the case of patients who must undergo interval surgery, it is possible to continue the chemotherapy and to offer surgery after 6 cycles of chemotherapy. For early stage endometrial cancer, in case of low and intermediate preoperative ESMO risk, hysterectomy with bilateral annexectomy associated with a sentinel lymph node procedure should be favored. It is possible to consider postponing surgery for 1 to 2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For high ESMO risk, it ispossible to favor the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) in order to omit pelvic and lumbar-aortic lymphadenectomies. CONCLUSION: During COVID-19 pandemic, patients suffering from cancer should not lose life chance, while limiting the risks associated with the virus."],"journal":"Gynecol Obstet Fertil Senol","authors":["Akladios, C","Azais, H","Ballester, M","Bendifallah, S","Bolze, P-A","Bourdel, N","Bricou, A","Canlorbe, G","Carcopino, X","Chauvet, P","Collinet, P","Coutant, C","Dabi, Y","Dion, L","Gauthier, T","Graesslin, O","Huchon, C","Koskas, M","Kridelka, F","Lavoue, V","Lecointre, L","Mezzadri, M","Mimoun, C","Ouldamer, L","Raimond, E","Touboul, C"],"date":"2020-03-31T11:00:00Z","year":2020,"_id":"32222433","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.gofs.2020.03.017","keywords":["covid-19","cancer gynecologique","guideline","gynaecological cancer","management","prise en charge","recommandation"],"locations":["ovarian"],"topics":["Treatment"],"weight":1,"_version_":1666138490231848961,"score":307.8151},{"pmid":32247066,"pmcid":"PMC7118621","title":"Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN group for the CNGOF.","text":["Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN group for the CNGOF.","INTRODUCTION: In the context of the COVID-19 pandemic, specific recommendations are required for the management of patients with gynecologic cancer. MATERIALS AND METHOD: The FRANCOGYN group of the National College of French Gynecologists and Obstetricians (CNGOF) convened to develop recommendations based on the consensus conference model. RESULTS: If a patient with a gynecologic cancer presents with COVID-19, surgical management should be postponed for at least 15 days. For cervical cancer, radiotherapy and concomitant radiochemotherapy could replace surgery as first-line treatment and the value of lymph node staging should be reviewed on a case-by-case basis. For advanced ovarian cancers, neoadjuvant chemotherapy should be preferred over primary cytoreduction surgery. It is legitimate not to perform hyperthermic intraperitoneal chemotherapy during the COVID-19 pandemic. For patients who are scheduled to undergo interval surgery, chemotherapy can be continued and surgery performed after 6 cycles. For patients with early stage endometrial cancer of low and intermediate preoperative ESMO risk, hysterectomy with bilateral adnexectomy combined with a sentinel lymph node procedure is recommended. Surgery can be postponed for 1-2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For patients of high ESMO risk, the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) should be applied to avoid pelvic and lumbar-aortic lymphadenectomy. CONCLUSION: During the COVID-19 pandemic, management of a patient with cancer should be adapted to limit the risks associated with the virus without incurring loss of chance.","J Gynecol Obstet Hum Reprod","Akladios, Cherif","Azais, Henri","Ballester, Marcos","Bendifallah, Sofiane","Bolze, Pierre-Adrien","Bourdel, Nicolas","Bricou, Alexandre","Canlorbe, Geoffroy","Carcopino, Xavier","Chauvet, Pauline","Collinet, Pierre","Coutant, Charles","Dabi, Yohann","Dion, Ludivine","Gauthier, Tristan","Graesslin, Olivier","Huchon, Cyrille","Koskas, Martin","Kridelka, Frederic","Lavoue, Vincent","Lecointre, Lise","Mezzadri, Matthieu","Mimoun, Camille","Ouldamer, Lobna","Raimond, Emilie","Touboul, Cyril","32247066"],"abstract":["INTRODUCTION: In the context of the COVID-19 pandemic, specific recommendations are required for the management of patients with gynecologic cancer. MATERIALS AND METHOD: The FRANCOGYN group of the National College of French Gynecologists and Obstetricians (CNGOF) convened to develop recommendations based on the consensus conference model. RESULTS: If a patient with a gynecologic cancer presents with COVID-19, surgical management should be postponed for at least 15 days. For cervical cancer, radiotherapy and concomitant radiochemotherapy could replace surgery as first-line treatment and the value of lymph node staging should be reviewed on a case-by-case basis. For advanced ovarian cancers, neoadjuvant chemotherapy should be preferred over primary cytoreduction surgery. It is legitimate not to perform hyperthermic intraperitoneal chemotherapy during the COVID-19 pandemic. For patients who are scheduled to undergo interval surgery, chemotherapy can be continued and surgery performed after 6 cycles. For patients with early stage endometrial cancer of low and intermediate preoperative ESMO risk, hysterectomy with bilateral adnexectomy combined with a sentinel lymph node procedure is recommended. Surgery can be postponed for 1-2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For patients of high ESMO risk, the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) should be applied to avoid pelvic and lumbar-aortic lymphadenectomy. CONCLUSION: During the COVID-19 pandemic, management of a patient with cancer should be adapted to limit the risks associated with the virus without incurring loss of chance."],"journal":"J Gynecol Obstet Hum Reprod","authors":["Akladios, Cherif","Azais, Henri","Ballester, Marcos","Bendifallah, Sofiane","Bolze, Pierre-Adrien","Bourdel, Nicolas","Bricou, Alexandre","Canlorbe, Geoffroy","Carcopino, Xavier","Chauvet, Pauline","Collinet, Pierre","Coutant, Charles","Dabi, Yohann","Dion, Ludivine","Gauthier, Tristan","Graesslin, Olivier","Huchon, Cyrille","Koskas, Martin","Kridelka, Frederic","Lavoue, Vincent","Lecointre, Lise","Mezzadri, Matthieu","Mimoun, Camille","Ouldamer, Lobna","Raimond, Emilie","Touboul, Cyril"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32247066","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.jogoh.2020.101729","keywords":["covid-19","guideline","gynaecological cancer","management"],"locations":["ovarian"],"topics":["Prevention"],"weight":1,"_version_":1666138492073148416,"score":306.28214},{"pmid":32337825,"title":"High-Immunological Risk Living Donor Renal Transplant during the COVID-19 Outbreak: Uncertainties and Ethical Dilemmas.","text":["High-Immunological Risk Living Donor Renal Transplant during the COVID-19 Outbreak: Uncertainties and Ethical Dilemmas.","We describe the challenges of performing a high-immunological risk living donor renal transplant during the COVID-19 outbreak. A 42-year-old lady with end-stage renal disease from lupus nephritis had failed peritoneal dialysis due to pleuro-peritoneal leak, failed vascular access creation due to early thrombosis and had recurrent dialysis catheter malfunction. The transplant from her husband was ABO-incompatible and had positive B cell flow crossmatch with multiple donor-specific antibodies. Neither alternative donors nor paired exchange candidates were available. Priority access to deceased donors is limited and unpredictable.","Am J Transplant","Ho, Quan Yao","Chung, Shimin Jasmine","Gan, Valerie Huei Li","Ng, Lay Guat","Tan, Ban Hock","Kee, Terence Yi Shern","32337825"],"abstract":["We describe the challenges of performing a high-immunological risk living donor renal transplant during the COVID-19 outbreak. A 42-year-old lady with end-stage renal disease from lupus nephritis had failed peritoneal dialysis due to pleuro-peritoneal leak, failed vascular access creation due to early thrombosis and had recurrent dialysis catheter malfunction. The transplant from her husband was ABO-incompatible and had positive B cell flow crossmatch with multiple donor-specific antibodies. Neither alternative donors nor paired exchange candidates were available. Priority access to deceased donors is limited and unpredictable."],"journal":"Am J Transplant","authors":["Ho, Quan Yao","Chung, Shimin Jasmine","Gan, Valerie Huei Li","Ng, Lay Guat","Tan, Ban Hock","Kee, Terence Yi Shern"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32337825","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/ajt.15949","topics":["Prevention"],"weight":1,"_version_":1666138494283546625,"score":264.89267}]}